Schizophrenia Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020

Feb. 24, 2012 - PRLog -- GlobalData’s analysis of the global schizophrenia therapeutics market suggests that the 2011 global market is was valued at $10.9 billion; this is inclusive of the markets of the US, the UK, Germany, France, Italy, Spain, Japan, Brazil, Russia, India and China. The schizophrenia therapeutics market has grown at a Compound Annual Growth Rate (CAGR) of 4.6% during 2002 - 2011. The dominance of atypical antipsychotics such as Zyprexa (olanzapine), Seroquel (quetiapine), Abilify (aripiprazole), Risperdal/Risperdal Consta and Geodon/Zeldox (ziprasidone) is a salient feature of the schizophrenia therapeutics market in the seven major markets (US, the UK, Germany, France, Italy, Spain and Japan). These drugs have approvals for multiple indications. In 2010, the global sales of Zyprexa were approximately $5 billion, followed by Seroquel with sales of approximately $4 billion, and Abilify with reported sales in excess of $2.5 billion. Johnson & Johnson, Eli Lilly, AstraZeneca, Bristol-Myers Squibb (BMS)/Otsuka Pharmaceuticals and Pfizer are the leading companies operating in the globaln schizophrenia therapeutics market. These large multinationals have been able to leverage their strong global presence to generate substantial revenues over the past couple of years.

The results of Phase III Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trials indicate that these atypical antipsychotics have been effective in treating schizophrenia. The Positive and Negative Syndrome Scale (PANSS) scores of Zyprexa (77.6), Abilify (76.4), Risperdal (75.6),
Seroquel (75.2) and Geodon (71.4) and the Clinical Global Impression (CGI) scores of Zyprexa (4.1), Abilify (4), Risperdal (4.2), Seroquel (4.1) and Geodon (3.9) provide evidence for the efficacy of these drugs. Weight gain, dizziness, akathisia, headache and extrapyramidal effects (although fewer extrapyramidal effects were reported then with the conventional antipsychotics) are the adverse events
associated with these atypical antipsychotics

The analysis of epidemiology of schizophrenia suggests that the prevalent, diagnosed and treated patient population for schizophrenia have registered a nominal growth in the last decade. It is estimated that this trend is likely to continue through the forecast period until 2020.

For Sample Pages, please click or add the below link to your browser:
http://globaldata.com/reportstore/RequestSamplePages.aspx...

The global schizophrenia therapeutics market is poised to witness a significant decline during the forecast period until 2020. The schizophrenia therapeutics market is likely to register negative growth due to the patent expiry of Zyprexa, Abilify, Seroquel and Risperdal Consta. It is estimated that the patent expiries will lead to a decline in the market at a negative CAGR of 5.4% to reach $6.6 billion during the period 2011 - 2020. The clinical pipeline consists of drugs with novel mechanisms of action in Phase III of clinical development; among these, cariprazine, zicronapine, RG1678 and LY2140023 are expected to be launched by 2020. However, the introduction of these novel Phase III drugs is unlikely to ensure complete recovery of the market valuations through 2020

GlobalData, the industry analysis specialist, has released its new report, “Schizophrenia Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global schizophrenia therapeutics market. The report provides comprehensive information on schizophrenia therapeutics market, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global schizophrenia therapeutics market. It analyses the treatment usage patterns in the global schizophrenia therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global schizophrenia therapeutics market. It quantifies the unmet need in the global schizophrenia therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Schizoph...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.